These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 32827160)
1. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. Damle B; Jen F; Sherman N; Jani D; Sweeney K J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160 [TBL] [Abstract][Full Text] [Related]
2. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454 [TBL] [Abstract][Full Text] [Related]
3. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050 [TBL] [Abstract][Full Text] [Related]
4. Retrospective study evaluating safety, clinical effect, and dosing of dalteparin for the treatment of venous thromboembolism in term neonates. Sherman N; Younus M; Wolter K; Victor S; Kairamkonda V; Adams E; Brotherton H; Boyle EM Pediatr Blood Cancer; 2024 Oct; 71(10):e31215. PubMed ID: 39054689 [TBL] [Abstract][Full Text] [Related]
5. No effect of norepinephrine dose on anti-Xa activity in critically ill patients . Meenks SD; Foudraine NA; Broen K; le Noble JLML; Janssen PKC Int J Clin Pharmacol Ther; 2020 Apr; 58(4):223-229. PubMed ID: 32000886 [TBL] [Abstract][Full Text] [Related]
6. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207 [TBL] [Abstract][Full Text] [Related]
7. FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients. Merino M; Richardson N; Reaman G; Ande A; Zvada S; Liu C; Hariharan S; De Claro RA; Farrell A; Pazdur R Pediatr Blood Cancer; 2020 Dec; 67(12):e28688. PubMed ID: 32896942 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071 [TBL] [Abstract][Full Text] [Related]
10. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. Schmid P; Brodmann D; Odermatt Y; Fischer AG; Wuillemin WA J Thromb Haemost; 2009 Oct; 7(10):1629-32. PubMed ID: 19624460 [TBL] [Abstract][Full Text] [Related]
11. Management of venous thromboembolism in patients with cancer: role of dalteparin. Linkins LA Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503 [TBL] [Abstract][Full Text] [Related]
12. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Kovacs MJ; Levine MN; Keeney M; Mackinnon KM; Lee AY Thromb Haemost; 2005 Jun; 93(6):1185-8. PubMed ID: 15968406 [TBL] [Abstract][Full Text] [Related]
13. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369 [TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience. Warad D; Rao AN; Mullikin T; Graner K; Shaughnessy WJ; Pruthi RK; Rodriguez V Thromb Res; 2015 Aug; 136(2):229-33. PubMed ID: 26026634 [TBL] [Abstract][Full Text] [Related]
15. Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients. van der Heijden CDCC; Ter Heine R; Kooistra EJ; Brüggemann RJ; Walburgh Schmidt JWJ; de Grouw EPLM; Frenzel T; Pickkers P; Leentjens J Br J Clin Pharmacol; 2022 Jun; 88(6):2982-2987. PubMed ID: 34965610 [TBL] [Abstract][Full Text] [Related]
16. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. Oldgren J; Johnston N; Siegbahn A Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482 [TBL] [Abstract][Full Text] [Related]
17. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM Crit Care; 2006; 10(3):R93. PubMed ID: 16790078 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Stöbe J; Siegemund A; Achenbach H; Preiss C; Preiss R Int J Clin Pharmacol Ther; 2006 Oct; 44(10):455-65. PubMed ID: 17063975 [TBL] [Abstract][Full Text] [Related]
19. Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring. van Bergen EDP; Huisman A; Welsing PMJ; de Winter MA; Rookmaaker MB; Kaasjager HAH; Nijkeuter M Neth J Med; 2019 Dec; 77(10):360-365. PubMed ID: 31880268 [TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach. Abe S; Chiba K; Suwa T Int J Clin Pharmacol Ther; 2013 Jun; 51(6):482-9. PubMed ID: 23587152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]